Evidence map›Paper›PMID 29184765›Full record

ArticleQuantitative imaging in medicine and surgery2017

The novel targets of DL-3-n-butylphthalide predicted by similarity ensemble approach in combination with molecular docking study.

Yan Wang, Wei Qi, Li Zhang, Zhenguang Ying, Ou Sha, Chunman Li, Lanhai Lü, Xiangyan Chen, Zhenzhong Li, Feng Niu and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Neurological Applications of Celery (Molecules (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Yan WangSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Wei QiDepartment of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang 050000, China.
Li ZhangDepartment of Physiology and Neurology, University of Connecticut, Storrs 06269USA.
Zhenguang YingDepartment of Anatomy, Histology and Developmental Biology, School of Basic Medical Sciences, Shenzhen University Health Science Centre, Shenzhen 518060, China.
Ou ShaDepartment of Anatomy, Histology and Developmental Biology, School of Basic Medical Sciences, Shenzhen University Health Science Centre, Shenzhen 518060, China.
Chunman LiDepartment of Anatomy, Histology and Developmental Biology, School of Basic Medical Sciences, Shenzhen University Health Science Centre, Shenzhen 518060, China.
Lanhai LüDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville 40202, USA.
Xiangyan ChenDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Zhenzhong LiDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Feng NiuCentral Institute of Pharmaceutical Research, Shijiazhuang Pharmaceutical Group Co., Ltd., Shijiazhuang 050035, China.
Fang XueDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Dong WangDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Tzi-Bun NgSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Lihong ZhangDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Second Hospital of Hebei Medical University · CNShenzhen University Health Science Center · CNChinese University of Hong Kong · CNHebei Medical University · CNPrince of Wales Hospital · CNShijiazhuang Yiling Pharmaceutical (China) · CNUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDL-3-n-butylphthalide (NBP) is a drug for treating acute ischemic stroke, and may play a neuroprotective role by acting on multiple active targets. The aim of this study was to predict the target proteins of NBP in mammalian cells.

methodsThe similarity ensemble approach search tool (SEArch), one of the commonly used public bioinformatics tools for target prediction, was employed in the experiment. The molecular docking of NBP to target proteins was performed by using the three-dimensional (3-D) crystal structure, substrate free. The software AutoDock Vina was used for all dockings. The binding targets of NBP were illustrated as 3-D and 2-D diagrams.

resultsFirstly, the results showed that NBP bounded to the same binding site on NAD(P)H quinone oxidoreductases (NQO1) as the substrate FAD, leading to competitive inhibition for the catalytic site with -7.2 kcal/mol. This might break the 3-D structure of NQO1 and bring about P53 degradation, resulting in a decrease of p53-mediated apoptosis in ischemic brain cells. Secondly, NBP might exert its therapeutic effect on acute ischemic stroke via modulating indoleamine 2,3-dioxygenase (IDO) bioactivity after associating with it. NBP could alleviate the depression following ischemic stroke by inhibiting IDO. Thirdly, NBP might modulate the function of NADH-ubiquinone oxidoreductase by competitively embedding itself into this complex, further affecting mitochondrial respiration in cerebrovascular diseases as an anti-oxidant agent.

conclusionsThree potential target proteins of NBP were identified, which may provide a novel aspect for better understanding the protective effects of NBP on the nervous system at the molecular level.

Indexed as

bioinformaticsDL-3-n-butylphthalide (NBP)indoleamine 2,3-dioxygenase (IDO)molecular targetsNADH-ubiquinone oxidoreductaseNAD(P)H quinone oxidoreductases

Identifiers

PMID29184765
PMCPMC5682405
OpenAlexW2765413914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.